Pure Global AI
NCT06305715Not yet recruiting

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Medical College of WisconsinPhase 2ClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Radiation Therapy
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Medical College of Wisconsin
Location
Milwaukee, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jul 15, 2024
End date
Jun 15, 2028
Enrollment
34 participants
Primary outcome

Progression Free Survival

Summary

This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the
 use of definitive radiation to the primary lung lesion prolongs progression-free survival
 (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC)
 patients who are subsequently placed on a tyrosine kinase inhibitor (TKI).

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06305715
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06305715 through Pure Global AI's free database. This Phase 2 trial is sponsored by Medical College of Wisconsin and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 34 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.